Kisspeptin.

Driving the pituitary and gonadal end of the reproductive hormone axis.

The reproductive axis runs in three stages. Gonadotropin-releasing hormone is secreted in pulses from the hypothalamus and acts on GnRH receptors on pituitary gonadotrope cells. Those cells release luteinizing hormone and follicle-stimulating hormone. LH and FSH then act on the gonads: in males LH drives Leydig cells to produce testosterone while FSH supports Sertoli cells and sperm production, and in females they govern follicular development, ovulation, and corpus luteum function. Sex steroids feed back on both the hypothalamus and pituitary to close the loop. The single most important feature of this pathway is that the pattern of stimulation determines the outcome, not just its presence. Brief, intermittent, pulsatile exposure to GnRH sustains LH and FSH release. Continuous exposure desensitises and downregulates the receptor, which after an initial surge shuts gonadotropin secretion down. This is why the same receptor is used both to switch the axis on, through pulsatile delivery, and to switch it off, through long-acting agonists used in prostate cancer, endometriosis, and precocious puberty. Anyone reasoning about a GnRH-targeting compound who ignores the delivery pattern will reach the wrong conclusion. Compounds here act at different levels. One is the natural decapeptide itself, engaging pituitary GnRH receptors directly. Another acts a step downstream: it is structurally similar to LH and binds the shared LH and chorionic gonadotropin receptor on gonadal cells, effectively substituting for LH and stimulating testosterone production or triggering final oocyte maturation depending on context. A third acts a step upstream, on the neurons that release GnRH in the first place. Because these compounds enter the axis at different points, they behave differently. Acting at the pituitary preserves gonadal feedback; acting directly on the gonad bypasses the pituitary entirely and does not require a functioning pituitary to work. Clinical grounding here is comparatively strong. Members of this group are approved medicines with defined indications in fertility medicine and endocrinology, and the physiology has been demonstrated in humans over decades. That established status applies to specific supervised medical uses. It does not extend to unsupervised use for hormone manipulation outside those indications, where dosing pattern errors can produce the opposite of the intended effect, and where suppression of the axis rather than stimulation is a real possibility.

Upstream neuronal control of GnRH release and reproductive-hormone pulsatility.

Kisspeptin sits above gonadotropin-releasing hormone in the reproductive hierarchy and is the reason the axis has a pulse at all. It signals through KISS1R, a Gq/11-coupled G-protein-coupled receptor formerly called GPR54, expressed densely on GnRH neurons in the hypothalamus. Receptor binding activates phospholipase C signalling, which depolarises those neurons and drives GnRH release into the hypophyseal portal circulation, and from there the pituitary secretes luteinizing hormone and, more modestly, follicle-stimulating hormone. The pathway's importance was established through human genetics rather than pharmacology. Loss-of-function mutations in KISS1R cause failure to enter puberty with low gonadotropins, and activating mutations are associated with precocious puberty. That is unusually clean evidence: it shows the receptor is not merely involved but required, which is a stronger claim than most peptide pathways can make. A specific population of kisspeptin neurons in the arcuate nucleus co-expresses neurokinin B and dynorphin, and these cells are widely regarded as the pulse generator for the whole axis. Neurokinin B provides the excitatory drive that starts each pulse and dynorphin provides the inhibition that ends it, producing the rhythmic output that GnRH neurons then translate into pulsatile secretion. Kisspeptin neurons are also where metabolic and steroid feedback signals converge, which is a plausible mechanistic bridge between energy availability and reproductive function. Administering kisspeptin therefore stimulates the axis in a way that is physiologically upstream, working through the body's own GnRH neurons rather than substituting for GnRH. In principle this preserves more of the natural regulatory structure. As with GnRH itself, the pattern matters: sustained exposure can desensitise the system rather than sustain it. On clinical relevance, this is a research tool rather than a treatment. Kisspeptin has been used in human studies as a probe of reproductive axis function and has been explored for triggering oocyte maturation in fertility settings, and its acute effect on LH in people is reproducible. It is not an approved medicine, there are no established therapeutic protocols, and its short circulating half-life makes practical use awkward. Claims about libido or hormonal enhancement outside supervised research go well beyond what the pathway evidence supports. It is also worth separating two distinct ideas that are often merged: kisspeptin's role as a necessary component of normal reproductive physiology is firmly established, while the proposition that supplying additional kisspeptin improves anything in a person with an intact axis is a separate claim that has not been demonstrated.

Controlled human administration studies repeatedly show an acute rise in LH, with a smaller effect on FSH.

Imaging studies in healthy men show modulation of limbic responses to sexual and emotional stimuli, which is a long way from a demonstrated libido treatment.

It has been explored as a diagnostic and ovulation-triggering tool in research settings, with no phase 3 efficacy trials and no approved product.

Sustained exposure can desensitize the receptor, and there is no long-term human safety data outside monitored trials.